Skip to content

Study of Safety and Efficacy of a Left Atrial Appendage Occulder

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02937025
Enrollment
154
Registered
2016-10-18
Start date
2017-01-31
Completion date
2020-01-31
Last updated
2016-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular Atrial Fibrillation, Stroke

Keywords

Nonvalvular atrial fibrillation, Stroke, Left Atrial Appendage Closure, Intervention

Brief summary

This study mainly evaluated the feasibility and safety of a kind of Left Atrial Appendage Occluders which is to prevent ischemic stroke caused by nonvalvular atrial fibrillation (AF)

Detailed description

Atrial fibrillation (AF) is a common arrhythmia, its incidence increases with age. Thrombosis shed off caused by AF is one of the major causes of stroke. Most patients with AF suffer ischemic stroke that the thrombosis was from the left atrial appendage(LAA). The majority of patients with atrial fibrillation, the blood clots come from the left atrial appendage, so close the left atrial appendage can reduce cycle thromboembolism of the patients with AF. Now patients have cardiac surgery and risk at left atrium related thromboembolism, the surgery has been conventional perform the left atrial appendage closed surgery. However, surgical left atrial appendage ligation is difficult to be completely closed to the left atrial appendage,internal medicine intervention methods of surgical closure the left atrial appendage is relatively simple, minimally invasive, high success rate and is expected to be widely used. Several versions of LAA occlusion devices have been developed.LAA occluder of Shanghai Push Medical Device Technology CO.td, consists of a fixed ball and a cover; The fixed ball composed of multiple umbrella and covered the ePTFE membrane.This study mainly evaluated the feasibility and safety of the new Left Atrial Appendage Occluder! Through the femoral vein puncture; insert inter atrial septum puncture device; puncture a small hole in the atrial septal, delivery sheath is inserted in the femoral vein puncture site and across the atrial septal reach the left atrial appendage, establishment of the channel. Through the built-channel sent the LAA occluder to the left atrial appendage by the delivery cable; The LAA occlude will be fixed in the left atrial appendage, close the entrance of the left atrial appendage meanwhile and block blood flow; then eliminate the risk of blood clots due to atrial fibrillation, prevention stroke.

Interventions

DEVICEThe Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td

Implanting the Occluder to close the left atrial appendage

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
Shenyang Military Region General Hospital of People's Liberation Army
CollaboratorUNKNOWN
West China Hospital
CollaboratorOTHER
Ruijin Hospital
CollaboratorOTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
CollaboratorOTHER
Zhejiang Provincial People's Hospital
CollaboratorOTHER
Fujian Medical University Union Hospital
CollaboratorOTHER
Ya-Wei Xu
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient is ≥18 years of age; * Chronic atrial fibrillation ≥3 months; paroxysmal, persistent or permanent non-valvular AF; * CHADS2-VAS score 2 or higher,HAS-BLED score 3 or higher; * Patient can understand the trial purpose, voluntarily join this clinical trial with informed consent; * Patient voluntarily completes the follow-up and follow-up inspection in accordance with the clinical trials process.

Exclusion criteria

1. A. Clinical

Design outcomes

Primary

MeasureTime frameDescription
Ischemic stroke12 months
Successful sealing of the LAA12 monthsTEE Criteria

Secondary

MeasureTime frameDescription
Component events12 monthsdeath, thromboembolism, device related complication and MACCE
Complication at puncture site12 months
Device performance assessed by TEE/TTE12 months

Contacts

Primary ContactShuang Li, MD
1210874@tongji.edu.cn086-15921799351
Backup ContactWei Chen, MD, PHD
18917684083@189.cn086-21-66308182

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026